Skip to main content

Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump

Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion less than it had expected.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.